Article
Cell Biology
Pengyun Li, Qiaohong Lin, Shiyang Sun, Ning Yang, Yu Xia, Shengjie Cao, Wenjuan Zhang, Qian Li, Haoxin Guo, Maoxiang Zhu, Yilong Wang, Zhibing Zheng, Song Li
Summary: This study identified the potential of dual targeting CB1 and ferroptosis as a promising therapeutic strategy for TNBC. By inhibiting CB1 and regulating lipid metabolism, the effectiveness of ferroptosis in TNBC cells can be enhanced, leading to tumor growth inhibition.
CELL DEATH & DISEASE
(2022)
Article
Multidisciplinary Sciences
Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S. Callander, Alan Rapraeger, M. Suresh, Fotis Asimakopoulos, Jing Zhang
Summary: This study found that ponatinib has moderate killing activity against multiple myeloma (MM) and strong synergism with trametinib (Tra) in vitro. However, ponatinib inhibits T cell function, which may partially counteract its synergistic killing effect with Tra in vivo.
SCIENTIFIC REPORTS
(2022)
Article
Cell Biology
Luciano Ferrada, Maria Jose Barahona, Matias Vera, Brent R. Stockwell, Francisco Nualart
Summary: The combination therapy of imidazole ketone erastin (IKE) and oxidized form of vitamin C (DHAA) can restore sensitivity to ferroptosis in previously resistant tumor cells and induce lipid droplet peroxidation, leading to ferroptosis.
CELL DEATH & DISEASE
(2023)
Article
Cell Biology
Qiujie Wang, Cheng Bin, Qiang Xue, Qingzhu Gao, Ailong Huang, Kai Wang, Ni Tang
Summary: The study revealed that GSTZ1 enhances sorafenib-induced ferroptosis by inhibiting the NRF2/GPX4 axis in HCC cells, and the combination therapy of sorafenib and GPX4 inhibitor RSL3 may be a promising strategy in HCC treatment.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Andrew M. Waters, Tala O. Khatib, Bjoern Papke, Craig M. Goodwin, G. Aaron Hobbs, J. Nathaniel Diehl, Runying Yang, A. Cole Edwards, Katherine H. Walsh, Rita Sulahian, James M. McFarland, Kevin S. Kapner, Thomas S. K. Gilbert, Clint A. Stalnecker, Sehrish Javaid, Anna Barkovskaya, Kajal R. Grover, Priya S. Hibshman, Devon R. Blake, Antje Schaefer, Katherine M. Nowak, Jennifer E. Klomp, Tikvah K. Hayes, Michelle Kassner, Nanyun Tang, Olga Tanaseichuk, Kaisheng Chen, Yingyao Zhou, Manpreet Kalkat, Laura E. Herring, Lee M. Graves, Linda Z. Penn, Hongwei H. Yin, Andrew J. Aguirre, William C. Hahn, Adrienne D. Cox, Channing J. Der
Summary: The study identified that suppression of BCAR1, TUBB3, or microtubule function can decrease levels of MYC protein and sensitize pancreatic cancer cells with KRAS mutation to ERK inhibition. The combination of dual SRC/tubulin inhibitor with an ERK inhibitor cooperates to reduce MYC protein and synergistically suppress the growth of KRAS mutant pancreatic cancer.
Article
Oncology
Yu-Xin Liao, Ji-Yang Lv, Zi-Fei Zhou, Tian-Yang Xu, Dong Yang, Qiu-Ming Gao, Lin Fan, Guo-Dong Li, Hai-Yang Yu, Kai-Yuan Liu
Summary: This study demonstrated that inhibition of CXCR4 sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death, suggesting that targeting the CXCR4/autophagy axis may be a promising therapeutic strategy to overcome chemotherapy resistance in osteosarcoma.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Hericka Bruna Figueiredo Galvao, Quynh Nhu Dinh, Jordyn M. Thomas, Flavia Wassef, Henry Diep, Alex Bobik, Christopher G. Sobey, Grant R. Drummond, Antony Vinh
Summary: The effect of reducing antibody-secreting cells (ASCs) on angiotensin II-induced hypertension was tested using the proteasome inhibitor bortezomib. ASCs and antibody levels were decreased, but hypertension was not affected.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Oncology
Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih-Feng Cho, Gang An, Lugui Qiu, Krista Kinneer, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Summary: Efforts are needed to enhance the efficacy and durability of CD38- and BCMA-based immunotherapies in human multiple myeloma. The novel immunomodulatory effects triggered by BCMA pyrrolobenzodiazepine (PBD) antibody drug conjugate (ADC) MEDI2228 have been investigated, showing enrichment of IFN I signaling and enhanced expression of IFN-stimulated genes in multiple myeloma cells, which can improve patient outcome.
CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Tinglei Huang, Fuli Li, Xiaojiao Cheng, Jianzheng Wang, Wenhui Zhang, Baiwen Zhang, Yao Tang, Qingli Li, Cong Zhou, Shuiping Tu
Summary: In this study, it was demonstrated that inhibiting the Wnt/β-catenin signaling pathway enhances the efficacy of PD-L1 blockade therapy, overcoming immune resistance mediated by CAFs. Knocking out PD-L1 in BMFs can restore sensitivity to PD-L1 blockade therapy in BMF-mixed tumors.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Seohyun Kim, Seong A. Kim, Gi-Hoon Nam, Yeonsun Hong, Gi Beom Kim, Yoonjeong Choi, Seokyoung Lee, Yuri Cho, Minsu Kwon, Cherlhyun Jeong, Sehoon Kim, In-San Kim
Summary: A targeted immunotherapeutic strategy involving local photodynamic therapy, a rho-kinase inhibitor, and PD-1/PD-L1 immune checkpoint blockade was proposed for uveal melanoma. This treatment approach demonstrated efficacy in promoting immunogenic clearance of primary tumors, preventing metastasis, and improving survival outcomes for patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Beatrice T. Wang, Tasnim Kothambawala, Ling Wang, Thomas J. Matthew, Susan E. Calhoun, Avneesh K. Saini, Maya F. Kotturi, Genevive Hernandez, Eric W. Humke, Marvin S. Peterson, Angus M. Sinclair, Bruce A. Keyt
Summary: IGM-8444, an engineered multivalent agonistic IgM antibody with high avidity to DR5, induces cancer cell apoptosis through efficient DR5 multimerization. It shows potent cytotoxicity in a broad range of solid and hematologic cancer cell lines, and exhibits synergistic effects when combined with chemotherapy or BCL-2 inhibition, without increasing hepatotoxicity, supporting its clinical development in cancer therapy.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Katharina H. Susek, Ysabel A. Schwietzer, Maria Karvouni, Mari Gilljam, Marton Keszei, Alamdar Hussain, Johan Lund, Muhammad Kashif, Andreas Lundqvist, Hans-Gustaf Ljunggren, Hareth Nahi, Arnika K. Wagner, Evren Alici
Summary: This study designed novel NK cell specific PD1-based chimeric switch receptors, which enhance the anti-tumor activity of NK cells by modifying the PD1 structure, and demonstrated that this strategy has potential in PD-L1(+) tumor immunotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Biotechnology & Applied Microbiology
Gerhard Hamilton
Summary: This article provides an overview of current trials aiming to enhance ICI regimens using avelumab in combination with chemotherapeutic agents, antiangiogenetic drugs, and immunomodulators. Predictive factors for this type of immunochemotherapy are discussed.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Oncology
Yingwei Pan, Li Yang, Yinbiao Cao, Han Jun, Haowen Tang, Wenwen Zhang, Tao Wan, Tianyu Jiao, Bingyang Hu, Shichun Lu
Summary: The aim of this study was to investigate the prognostic factors in patients with Barcelona Clinic Liver Cancer stage C HCC who received salvage surgery after conversion therapy. The results showed that lower AFP level after conversion therapy and MVI II were associated with higher overall survival and lower recurrence.
TRANSLATIONAL CANCER RESEARCH
(2023)
Editorial Material
Gastroenterology & Hepatology
Ann-Lii Cheng
Summary: In 2020, combination treatments have significantly improved the efficacy of systemic therapy for HCC, with different drug combinations showing high therapeutic effects, establishing new standards and directions for future treatment of HCC.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
Kuo-Hsing Chen, Liang-In Lin, Chang-Tsu Yuan, Li-Hui Tseng, Yu-Liang Chao, Yi-Hsin Liang, Jin-Tung Liang, Been-Ren Lin, Ann-Lii Cheng, Kun-Huei Yeh
Summary: In Taiwan, distinct clinicopathological features were identified for CIMP-high CRC among different age groups. Our data suggest the association between BMI >= 27.5 kg/m(2) and CIMP-high CRC in patients younger than 50 years.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim, Hongming Pan, Kun-Ming Rau, Hye Jin Choi, Joong-Won Park, Jee Hyun Kim, Chia Jui Yen, Ho Yeong Lim, Dongli Zhou, Josef Straub, Juergen Scheele, Karin Berghoff, Shukui Qin
Summary: This study evaluated the efficacy of the MET inhibitor Tepotinib in Asian patients with aHCC, showing improved time to progression and better tolerability compared to sorafenib.
BRITISH JOURNAL OF CANCER
(2021)
Review
Oncology
Sung-Hsin Kuo, Kun-Huei Yeh, Chung-Wu Lin, Jyh-Ming Liou, Ming-Shiang Wu, Li-Tzong Chen, Ann-Lii Cheng
Summary: The prevalence of HP-negative gastric MALT lymphoma has increased, while HP-positive gastric MALT lymphoma has decreased. Some case studies have shown that a first-line HP eradication therapy (HPE)-like regimen can result in complete remission for some patients with localized HP-negative gastric MALT lymphoma. Previous sporadic reports have also indicated that some patients with extragastric MALT lymphoma can respond to antibiotic treatment.
Article
Oncology
Yu-Yun Shao, Pai-Sheng Chen, Liang-In Lin, Bin-Shyun Lee, Andrew Ling, Ann-Lii Cheng, Chiun Hsu, Da-Liang Ou
Summary: This study identified miR-10b-3p as a potential biomarker for predicting sorafenib efficacy in advanced HCC patients and confirmed its mechanism of action.
BRITISH JOURNAL OF CANCER
(2022)
Review
Virology
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen
Summary: Ropeginterferon alfa-2b is a promising treatment option for MPN and chronic viral hepatitis due to its favorable pharmacokinetic profile and demonstrated efficacy in clinical studies. Administered once every two weeks, it has shown to be well-tolerated and effective in treating chronic hepatitis B, C, and D.
Review
Oncology
Chiao-Ling Li, Shiou-Hwei Yeh, Pei-Jer Chen
Summary: Cell-free tumor DNA (ctDNA) is a promising tumor marker that can reflect tumor burden, behavior, and prognosis. However, there are still challenges to be addressed before ctDNA can be used as a tumor marker. We propose using exogenous viral DNA integration to generate virus-host chimera DNA (vh-DNA) as a potential new biomarker. vh-DNA may overcome detection problems and serve as a universal marker for monitoring tumor expansion or burden related to oncogenic viruses.
Article
Oncology
Kuo-Hsing Chen, Chia-Lang Hsu, Yu-Li Su, Chang-Tsu Yuan, Liang-In Lin, Jia-Huei Tsai, Yi-Hsin Liang, Ann-Lii Cheng, Kun-Huei Yeh
Summary: This study found that the immune contexture in the tumor microenvironment is closely associated with prognosis in patients with metastatic BRAF V600E mutant colorectal cancer. High expression of immune genes and complement activation are correlated with poor prognosis, and the complement score is strongly correlated with tumor-associated macrophage M2 signatures.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Yu-Yun Shao, Hung-Wei Hsu, Rita Robin Wo, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu
Summary: CDK9 inhibitors have been found to have potent anti-proliferative and apoptosis-inducing activities against HCC cells, while inhibiting downstream signaling molecules' phosphorylation. Animal experiments have confirmed the inhibitory effects of CDK9 inhibitors on HCC. Overexpression of CDK9 reduced the efficacy of CDK9 inhibitors, while knockdown of CDK9 expression reduced the proliferative activities of HCC cells.
Article
Medicine, General & Internal
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Jo-Hsuan Wu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study found a strong correlation between serum M2BPGi levels and the severity of hepatic fibrosis in patients with HCV infection, and identified specific cutoff values that can be used for accurate diagnosis.
Article
Gastroenterology & Hepatology
Chiao-Ling Tsai, Po-Sheng Yang, Feng-Ming Hsu, Ann-Lii Cheng, Wan-Ni Yu, Jason Chia-Hsien Cheng
Summary: This study investigated the effect of TOP1 inhibition and DNA-PKcs/RNF144A mechanism on radiosensitization mediated by natural killer (NK) cells in radiation therapy (RT). The results showed that TOP1 inhibitors and RT had a synergistic effect on hepatocellular carcinoma (HCC) cells, enhancing the anti-HCC effect of RT through increased DNA damage and DNA-PKcs signaling. RNF144A mediated DNA-PKcs ubiquitination and provided a reason for the difference in radiosensitization effect between HCC cells.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Oncology
Yu-Chieh Tsai, Tzu-Yin Wang, Chia-Lang Hsu, Wei-Chou Lin, Jyun-Yu Chen, Jia-Hua Li, Yeong-Shiau Pu, Ann-Lii Cheng, Jason Chia-Hsien Cheng, Sheng-Fang Su
Summary: This study found that inhibiting HDAC6 can enhance the radiosensitivity of bladder cancer and reduce the expression of genes related to cell migration, angiogenesis, and metastasis induced by radiotherapy, thereby improving therapeutic efficacy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Article
Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.
